Self‐Generating Gold Nanocatalysts in Autologous Tumor Cells for Targeted Catalytic Immunotherapy

Abstract

Employing tumor whole cells for tumor immunotherapy is a promising tumor therapy proposed in the early stage, but its therapeutic efficacy is weakened by the methods of eliminating pathogenicity and the mass ratio of the effective antigen carried by itself. Here, by adding gold ion to live cancer cells in the microfluidic droplets, w e obtain dead tumor whole cells with NIR‐controlled catalytic ability whose pathogenicity is removed while plenary tumor antigens, major structure, and homing ability are reserved. The engineered tumor cell (Cell‐Au) with the addition of prodrug provides 1O2 in an O2‐free Russell mechanism, which serves better in a hypoxic tumor microenvironment. This tumor whole‐cell catalytic vaccine (TWCV) promotes the activation of dendritic cells and the transformation of macrophages into tumor suppressor phenotype. In 4T1 tumor‐bearing mice, the Cell‐Au‐based vaccine supports the polarization of cytotoxicity T cells, resulting in tumor eradication and long‐term animal survival. Compared with antigen vaccines or adoptive cell therapy which takes months to obtain, this TWCV can be prepared in just a few days with satisfactory immune activation and tumor therapeutic efficacy, which provides an alternative way for the preparation of personalized tumor vaccines across tumor types and gives immunotherapy a new path.This article is protected by copyright. All rights reserved